FDA Issues Warning Letter to CDMO Simtra Over Contamination Failures
The U.S. Food and Drug Administration issued a warning letter to Simtra Biopharma Solutions after an inspection revealed significant contamination-related GMP violations at its sterile manufacturing facility in Halle, Germany. Inspectors identified repeated microbial recoveries, aseptic processing failures, and weak contamination control systems. The findings highlight serious risks, sterile drug production, and regulatory expectations in global CDMO operations.
FDA Issues Warning Letter to Simtra Following Germany Inspection Findings
The FDA issued the warning letter following an inspection carried out between September 18 and 26 last year at Simtra’s facility in Halle, Germany. Inspectors found significant contamination control failures in aseptic manufacturing areas. The company, previously known as Baxter BioPharma Solutions until its rebrand in 2023, now faces formal regulatory scrutiny due to GMP deviations identified during the inspection.
FDA Flags Aseptic Processing Failures and Contamination Risks at Simtra
Inspectors reported that Simtra failed to maintain proper controls in aseptic processing environments. The FDA highlighted the use of an unspecified liquid for rinsing surfaces in sterile areas, combined with excessively long deadlegs in piping systems. These structural conditions created stagnant zones that increased contamination risks and reduced cleaning efficiency across critical production lines, leading to higher microbial control challenges within sensitive sterile manufacturing operations.
FDA Finds 47 Microbial Contamination Cases at Simtra Facility
Between June 2023 and September 2025, routine testing at the facility recorded at least 47 microbial recoveries. Fourteen of these exceeded acceptable limits. Environmental monitoring inside ISO 5 cleanrooms and Restricted Access Barrier Systems (RABS) also showed repeated presence of gram-negative organisms, including Sphingomonas, Methylobacterium, and Cupriavidus species. These findings indicated persistent microbial control issues within sterile zones.
FDA Identifies GMP Procedure Failures at Simtra Biopharma
The FDA also identified gaps in written procedures designed to prevent microbiological contamination. Simtra did not establish or consistently follow adequate documentation for sterile drug production. This lack of procedural control contributed to ongoing contamination risks and raised concerns about the overall robustness of the company’s quality system under GMP requirements.
Simtra Expands US Manufacturing Footprint Despite FDA Regulatory Pressure
While facing regulatory action in Germany, Simtra continued its manufacturing expansion in the United States. The company acquired a 65-acre site in Bloomington, Indiana, adding approximately 300,000 square feet of production space for fill-finish operations. This investment forms part of a broader capacity expansion strategy announced separately from a $250 million development program.
FDA Warning Letter Highlights Sterile Manufacturing Compliance Risks
The FDA warning letter places additional pressure on sterile manufacturers operating CDMO facilities across global markets. The findings in Halle highlight ongoing challenges in contamination control, especially in high-risk aseptic environments. Regulatory scrutiny continues to intensify around environmental monitoring, system design, and adherence to GMP standards in sterile drug production.
For teams working in sterile GMP environments and facing contamination risks, robust validation and qualification are critical to maintain control and ensure compliance across the full system lifecycle.
Explore Qualification and Validation for GMP-Regulated Systems for more details.
Source: Fiercepharma.Com